/

Sociétés

D&

Non vérifié

D&D Pharmatech, Inc.

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

4 communiqués de presse

Voir tous les communiqués de presse

16/06/2025

Biotechnologie

Santé

Industrie pharmaceutique

Médecine - Divers

Industrie

D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health

Source

D&D Pharmatech, Inc.

Émetteur

1.00

0

03/02/2025

Santé

Hygiène alimentaire

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

Industrie

D&D Pharmatech Announces Completion of Patient Enrollment for a 48-Week Phase 2 Trial Evaluating the Effectiveness of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist, in the Treatment of MASH

Source

D&D Pharmatech, Inc.

Émetteur

1.00

0

21/08/2024

Hygiène alimentaire

Santé

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

D&D Pharmatech Announces Initiation of Dosing in a Phase 2 Trial Designed to Evaluate the Efficacy and Safety of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist in Overweight/Obese Subjects with MASLD/MASH

Source

D&D Pharmatech, Inc.

Émetteur

1.00

0

02/04/2024

Accessoires

Vitrines/Shopping

Médecine - Divers

D&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH/MASH

Source

D&D Pharmatech, Inc.

Émetteur

1.00

0

Followers

0

Compatibilité

0